Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin

Xie X, McGregor M
Record ID 32012000926
Authors' recommendations: • The applicant intends to use the VerifyNow test to detect those patients at increased risk of arterial thrombotic events due to Clopidogrel resistance. Patients found to be clopidogrel resistant will be treated with other thienopyridine drugs. • The VerifyNow test is easy to use and is sufficiently accurate for this purpose. • The cost of this intervention for approximately 100 selected patients per year will be approximately $8,400. There will be no increased use of beds or other hospital services. • This intervention will probably result in improved patient outcomes. However, it is an intervention that has not previously been used and it's value is still unproven. It should therefore be considered an experimental intervention.
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Coronary Artery Disease
  • Platelet Function Tests
  • Aspirin
  • Ticlopidine
  • Point-of-Care Systems
Organisation Name: Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address: Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
Contact Email:
Copyright: Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.